Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma

NCT04506138 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Camrelizumab
DRUG: Paclitaxel for Injection (Albumin Bound)
DRUG: Carboplatin

Sponsor

Zhejiang Cancer Hospital